US EditionDutch Biotech Laigo Bio Bags €17m in Oversubscribed Seed Round - European Biotechnology Magazine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Dutch biotech Laigo Bio bags €17m in oversubscribed seed round - European Biotechnology Magazine
Membrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s bispecific antibody platform for hard-to-treat targets. The post Dutch biotech Laigo Bio bags €17m in oversubscribed seed round appeared first on European Biotechnology Magazine.
The main investor in the biotechnology network in Portugal invested four billion euros in the Gica biotechnol based in Utrecht, which develops innovative treatments for oncology and makes autoimunes.
Laigo Bio completes final close of oversubscribed seed financing of 17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, The Netherlands, March 23, 2026 (GLOBE NEWSWIRE) — Laigo Bio (“Laigo”), a biotech company […] The post Laigo Bio completes final close of oversubscribed seed financing…
Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering […] The post Laigo Bio completes final close of oversubscribed seed financing of €17…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
